In another study, MIPD was used to create D-peptides with high affinity for the microtubule-binding protein Tau, preventing selfaggregation in the treatment of tauopathies. The hexapeptides PHF6 (VQIINK) and PHF6* (VQIVYK) were found to promote Tau aggregation in tauopathies such as Alzheimer's disease, and their enantiomers have been used as a target for MIPD. Notably, two peptide candidates, MMD3 and MMD3rev, demonstrated cellpenetrating properties, with the ability to cross the cell membrane of neurons.